CN110777148B - DNA sequences for expression of FGF-2 and methods for producing FGF-2 - Google Patents
DNA sequences for expression of FGF-2 and methods for producing FGF-2 Download PDFInfo
- Publication number
- CN110777148B CN110777148B CN201910543546.4A CN201910543546A CN110777148B CN 110777148 B CN110777148 B CN 110777148B CN 201910543546 A CN201910543546 A CN 201910543546A CN 110777148 B CN110777148 B CN 110777148B
- Authority
- CN
- China
- Prior art keywords
- fgf2
- fgf
- construct
- pnc1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 title claims abstract description 136
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 title claims abstract description 136
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000014509 gene expression Effects 0.000 title abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 50
- 238000000746 purification Methods 0.000 claims abstract description 31
- 239000013600 plasmid vector Substances 0.000 claims abstract description 29
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 19
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 11
- 238000001890 transfection Methods 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000017730 intein-mediated protein splicing Effects 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 17
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 7
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 abstract description 17
- 230000004071 biological effect Effects 0.000 abstract description 7
- 238000010276 construction Methods 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- 101150019331 FGF2 gene Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000001976 enzyme digestion Methods 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000012154 double-distilled water Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000000508 neurotrophic effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001052030 Mus musculus Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 241000424623 Nostoc punctiforme Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000006334 disulfide bridging Effects 0.000 description 2
- 230000003241 endoproteolytic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108010071146 DNA Polymerase III Proteins 0.000 description 1
- 102000007528 DNA Polymerase III Human genes 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a DNA sequence for expressing FGF-2, wherein the sequence is shown in SEQ ID NO.1 or SEQ ID NO.2 or a complementary sequence thereof. The invention also provides a construct, wherein the construct comprises a DNA sequence shown in SEQ ID NO.1 or SEQ ID NO.2 between EcoRI and NotI restriction sites of the plasmid vector or a complementary sequence thereof. The invention also provides a preparation method and application of the construct. In addition, the invention also provides a method for preparing FGF-2, wherein the method comprises the following steps: a. culturing the cells: culturing a mammalian cell; b. transfection: transfecting the construct into the mammalian cells obtained in step a; c. and (3) purification: FGF-2 was purified by affinity chromatography. The DNA sequence for expressing FGF-2 and the construction thereof provided by the invention can obviously improve the expression of FGF-2 with biological activity, thereby greatly reducing the cost for preparing and purifying FGF-2.
Description
Technical Field
The invention relates to a DNA sequence for expressing FGF-2, a construct containing the DNA sequence, a preparation method of the construct, application of the construct in expressing FGF-2, and a method for preparing FGF-2.
Background
FGF2 is a very valuable protein in the pharmaceutical and health care industries. FGF2 is an effective therapeutic protein for the treatment of neurodegenerative diseases, heart disease, angiogenesis, difficult-to-heal wounds and bone fractures; it also plays an important role in the large-scale production of stem cells.
Coli has long been used for purification of recombinant proteins [1-4] due to low production cost, high replication rate, and high productivity. However, the use of prokaryotic expression systems often encounters obstacles in the purification of mammalian proteins due to toxicity caused by foreign proteins, lack of correct protein folding and post-translational modification [5,6 ]. Scientists have used eukaryotic hosts such as yeast and insect cells to overcome these limitations for many years [7 ]. Nevertheless, the use of cultured cells of human origin for human-derived protein expression appears to be intuitive. Indeed, an increasing trend has arisen towards the production of recombinant proteins using mammalian cells [8,9 ].
Currently, one of the most widely used host systems for FGF2 production and purification is bacteria. However, simple prokaryotes lack the necessary post-translational modifications, including splicing, glycosylation and disulfide bonding, activity and solubility of the protein for purification. The natural folding of the purified protein is critical to its function and solubility. Protein aggregates or inclusion bodies are often found when eukaryotic proteins are expressed in bacterial systems. Methods involving inducing proteins or denaturing and renaturing protein aggregates at lower temperatures do not always produce good yields. Therefore, the preparation and purification of biologically active FGF2 is extremely expensive ($ 4000/mg), which prevents its widespread use.
Fusion of affinity tags such as polyhistidine (His-tag), glutathione S-transferase (GST) or Calmodulin Binding Peptide (CBP) to target proteins is a common strategy for protein purification [10 ]. The tag provides a simple, simplified purification scheme for crude cell lysates. Although the tag may be removed after purification, some additional amino acids are usually left on the cleaved protein derivative. These additional amino acids, although rare, can alter the folding and thus alter its native form [11-14 ]. Recombinant proteins with additional and unwanted amino acids may lead to irreversible deleterious effects, bind off-target receptors, and may lead to cancer [15,16] and allergy [16,17 ]. Recently, many groups have reported the use of protein introns or inteins to facilitate the purification of unlabeled proteins [18-21 ]. Inteins are self-cleaving elements in naturally occurring proteins. The first identified intein was found, the VMA gene encoding vascular ATPase, where the intein was cleaved and then the N-and C-terminal exteins were ligated to produce a functional full-length protein [19-24 ]. Now that over 400 inteins have been found in many organisms, scientists have taken advantage of this self-excision property in the field of protein purification. Site-specific, precise cleavage of inteins can produce human-identical protein products when designed appropriately [23,25 ].
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a DNA sequence for expressing FGF-2, which is characterized in that the sequence is shown as SEQ ID NO. 1:
CCGGCTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCCACCAG GACACTTCAAAGATCCGAAGAGGCTTTACTGCAAGAATGGTGG ATTTTTCCTCCGCATCCATCCAGACGGTCGGGTGGACGGCGTAC GGGAGAAATCCGATCCGCATATAAAGCTGCAGCTGCAAGCTGA AGAACGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTAATAGG TACCTTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCTAAGTG CGTGACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTCAAACA ATTATAACACCTATAGGTCAAGAAAGTATACGAGCTGGTACGT TGCCCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCAAAACA GGCCCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGTGCCAA GTCTTAATAATAA, or the complement thereof.
The invention also provides another DNA sequence for expressing FGF-2, which is characterized in that the sequence is shown as SEQ ID NO. 2:
CATCATCACCATCACCACGCCGAGTACTACGAGACCGAGATCC TGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATCGTGGA GAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACAACGGC AACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAGGGGCG AGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGCCTGAT CAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACGGCCAG ATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGACCTGA TGAGGGTGGACAACCTGCCCAACGCCGAGTACTACGAGACCGA GATCCTGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATC GTGGAGAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACA ACGGCAACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAG GGGCGAGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGC CTGATCAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACG GCCAGATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGA CCTGATGAGGGTGGACAACCTGCCCAACCCGGCTCTCCCAGAG GATGGCGGCTCAGGAGCCTTTCCACCAGGACACTTCAAAGATC CGAAGAGGCTTTACTGCAAGAATGGTGGATTTTTCCTCCGCATC CATCCAGACGGTCGGGTGGACGGCGTACGGGAGAAATCCGATC CGCATATAAAGCTGCAGCTGCAAGCTGAAGAACGAGGGGTGGT TAGCATAAAGGGCGTGTGTGCTAATAGGTACCTTGCCATGAAA GAAGACGGACGGCTCCTCGCTTCTAAGTGCGTGACCGACGAGT GCTTCTTCTTTGAGCGGCTAGAGTCAAACAATTATAACACCTAT AGGTCAAGAAAGTATACGAGCTGGTACGTTGCCCTTAAGCGGA CCGGCCAGTACAAGCTTGGTAGCAAAACAGGCCCTGGCCAGAA GGCTATCCTCTTCCTCCCTATGAGTGCCAAGTCTTAATAATAA, or the complement thereof.
In another aspect, the invention provides a construct comprising the DNA sequence shown in SEQ ID No.1 or the complement thereof between the EcoRI and NotI restriction sites of the plasmid vector or the DNA sequence shown in SEQ ID No.2 or the complement thereof between the EcoRI and NotI restriction sites of the plasmid vector.
In another aspect, the present invention provides a method for preparing a construct, comprising the steps of:
a. synthesizing a DNA sequence shown in SEQ ID NO.1 containing restriction sites of EcoRI and NotI or a complementary sequence thereof; or synthesizing a DNA sequence shown in SEQ ID NO.2 containing EcoRI and NotI restriction enzyme cutting sites or a complementary sequence thereof;
b. digesting the plasmid vector with EcoRI and NotI, and recovering the large fragment;
c. and (c) connecting the DNA sequence obtained in the step a or a complementary sequence thereof with the large fragment obtained in the step b by using ligase.
d. And c, transfecting the cell with the ligation product obtained in the step c, screening positive clones, and extracting plasmids.
In another aspect, the invention provides the use of a construct provided herein for the expression of FGF-2.
In another aspect, the present invention provides a method for preparing FGF-2, the method comprising:
a. culturing the cells: culturing a mammalian cell;
b. transfection: transfecting the mammalian cells obtained in step a with the construct as described above;
c. and (3) purification: FGF-2 was purified by affinity chromatography.
The DNA sequence and the construction body thereof for expressing FGF-2 provided by the invention can obviously improve the expression level of FGF-2, and the expressed FGF-2 is basically soluble, and the biological activity thereof is equivalent to that of the commercially available FGF-2. Therefore, by adopting the construct provided by the invention to express FGF-2, the expression of FGF-2 with biological activity can be obviously improved, and the cost for preparing and purifying FGF-2 can be greatly reduced.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the invention without limiting the invention.
FIG. 1 is a schematic representation of the FGF2 construct and the his-DnaE-FGF2 construct. (A) DNA for the mature functional fragment of the FGF2 gene was synthesized and cloned into the pcDNA3.1(+) vector under the control of the CMV enhancer/promoter to form the pcDNA3.1-FGF2 construct. (B1) Synthesizing NF-kB binding sites and CREB binding sites, and cloning the NF-kB binding sites and the CREB binding sites behind a CMV promoter to form a pNC1 vector; (B2) the DNA of the mature functional fragment of the FGF2 gene was then cloned into pNC1 vector to form pNC1-FGF2 construct. (C) The 6xhis tag and Npu DnaE intein gene were fused to FGF2 by fusion PCR and cloned into pNC1 vector to form pNC1-6xhis-DnaE-FGF2 construct.
FIG. 2 shows the expression of the mature functional fragment FGF2 protein in HEK293T cells. (A) pcDNA3.1-FGF2 and pNC1-FGF2 constructs were transfected into HEK293T cells and whole cell lysates were analyzed by Western blotting at the indicated time points. (B) Densitometric analysis normalized to (a) relative β -actin. The pNC1-FGF2 construct showed higher expression levels at 24 hours, 36 hours and 48 hours (p <0.01, p < 0.001; n ═ 5 at each time point) than the pcdna3.1-FGF2 construct. (C) Supernatants (S) and pellets (P) from cell lysates were analyzed by western blot. FGF2(+ ve) was purchased commercially as a positive control. For both pcDNA3.1-FGF2 and pNC1-FGF2 constructs, FGF2 expressed by HEK293T was quite soluble.
Fig. 3 is a purification of FGF2 expressed in HEK293T cells. (A) Whole cell lysates and eluates from size exclusion chromatography samples were subjected to SDS-PAGE and stained with coomassie brilliant blue. (B) Samples from (a) were lyophilized and reconstituted in 0.1x PBS and then analyzed by silver staining after SDS-PAGE. Only 1 weak band (indicated by arrow) was observed in purified FGF 2.
Fig. 4 is a bioassay of purified FGF 2. (A) MTT assay to measure the effect of FGF2 on cell viability of C2C12 cells relative to PBS control. At the indicated time points, it was observed that 1ng/mL of commercial and purified FGF2 was able to induce cell growth in the culture medium (n-3). (B) Commercial and purified FGF2 was added to the medium at a concentration of 2ng/mL for 3 days. Phase contrast micrographs were taken on day 0 and day 3. Prolonged neurite outgrowth (indicated by arrows) was observed in PC12 cells 3 days after FGF2 treatment.
FIG. 5 shows the expression of the mature functional fragment FGF2 protein in HEK293T cells and the purification of FGF2 by intein-assisted cleavage. The pNC1-6xhis-DnaE-FGF2 construct was transfected into HEK293T cells, the medium was collected and spun at 2,000g for 10min to remove cell debris, and filtered through a 0.45 μm filter. The protein was purified by Ni-NTA affinity chromatography. Cleavage of the DnaE intein was induced in cleavage buffer. Starting 2 hours after induction, the full-length his-DnaE-FGF2 protein (band indicated by x) was cleaved into FGF2 (band indicated by #). Lysis was complete after 6 hours post-induction.
Figure 6 is a bioassay of purified and endoproteolytically cleaved FGF 2. (A) MTT assay to measure the effect of FGF2 on cell viability of C2C12 cells relative to PBS control. Both purified and endoproteolytic FGF2 were observed to be able to induce cell growth at the indicated time points at 1ng/mL in the culture medium (n-3). (B) 2ng/mL of purified and intein-cleaved FGF2 was added to the medium for 3 days. Phase contrast micrographs were taken on day 0 and day 3. Prolonged neurite outgrowth (indicated by arrows) was observed in PC12 cells 3 days after FGF2 treatment.
Detailed Description
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to the embodiments with reference to the attached drawings.
The invention provides a DNA sequence for expressing FGF-2, which is characterized in that the sequence is shown in SEQ ID NO. 1:
CCGGCTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCCACCAG GACACTTCAAAGATCCGAAGAGGCTTTACTGCAAGAATGGTGG ATTTTTCCTCCGCATCCATCCAGACGGTCGGGTGGACGGCGTAC GGGAGAAATCCGATCCGCATATAAAGCTGCAGCTGCAAGCTGA AGAACGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTAATAGG TACCTTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCTAAGTG CGTGACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTCAAACA ATTATAACACCTATAGGTCAAGAAAGTATACGAGCTGGTACGT TGCCCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCAAAACA GGCCCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGTGCCAA GTCTTAATAATAA, or the complement thereof.
The invention also provides a DNA sequence for expressing FGF-2, which is characterized in that the sequence is shown in SEQ ID NO. 2:
CATCATCACCATCACCACGCCGAGTACTACGAGACCGAGATCC TGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATCGTGGA GAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACAACGGC AACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAGGGGCG AGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGCCTGAT CAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACGGCCAG ATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGACCTGA TGAGGGTGGACAACCTGCCCAACGCCGAGTACTACGAGACCGA GATCCTGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATC GTGGAGAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACA ACGGCAACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAG GGGCGAGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGC CTGATCAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACG GCCAGATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGA CCTGATGAGGGTGGACAACCTGCCCAACCCGGCTCTCCCAGAG GATGGCGGCTCAGGAGCCTTTCCACCAGGACACTTCAAAGATC CGAAGAGGCTTTACTGCAAGAATGGTGGATTTTTCCTCCGCATC CATCCAGACGGTCGGGTGGACGGCGTACGGGAGAAATCCGATC CGCATATAAAGCTGCAGCTGCAAGCTGAAGAACGAGGGGTGGT TAGCATAAAGGGCGTGTGTGCTAATAGGTACCTTGCCATGAAA GAAGACGGACGGCTCCTCGCTTCTAAGTGCGTGACCGACGAGT GCTTCTTCTTTGAGCGGCTAGAGTCAAACAATTATAACACCTAT AGGTCAAGAAAGTATACGAGCTGGTACGTTGCCCTTAAGCGGA CCGGCCAGTACAAGCTTGGTAGCAAAACAGGCCCTGGCCAGAA GGCTATCCTCTTCCTCCCTATGAGTGCCAAGTCTTAATAATAA, or the complement thereof. The DNA sequence fuses the Npu DnaE intein gene to facilitate intein-mediated separation and purification.
The invention also provides a construct which comprises the DNA sequence shown in SEQ ID No.1 between the EcoRI and NotI restriction sites of the plasmid vector or is the complementary sequence thereof, or the construct which comprises the DNA sequence shown in SEQ ID No.2 between the EcoRI and NotI restriction sites of the plasmid vector or is the complementary sequence thereof.
For the construct of the present invention, although there is no particular requirement for a plasmid, in order to increase the expression level of FGF-2, in a preferred embodiment, the plasmid vector is pcDNA3.1(+) or pNC1, more preferably pNC 1.
In order to further increase the expression level of FGF-2 and to facilitate purification, in a preferred embodiment the construct comprises the DNA sequence shown in SEQ ID NO.2 or the complement thereof between the EcoRI and NotI restriction sites of a plasmid vector, pNC 1.
The invention also provides a preparation method of the construct, which is characterized by comprising the following steps:
a. synthesizing a DNA sequence shown in SEQ ID NO.1 containing restriction sites of EcoRI and NotI or a complementary sequence thereof; or synthesizing a DNA sequence shown in SEQ ID NO.2 containing EcoRI and NotI restriction enzyme cutting sites or a complementary sequence thereof;
b. digesting the plasmid vector with EcoRI and NotI, and recovering the large fragment;
c. and (c) connecting the DNA sequence obtained in the step a or a complementary sequence thereof with the large fragment obtained in the step b by using ligase.
d. And c, transfecting the cell with the ligation product obtained in the step c, screening positive clones, and extracting plasmids.
In a preferred embodiment, the plasmid vector is pcDNA3.1(+) or pNC1, more preferably pNC 1.
The invention also provides the use of the construct in the expression of FGF-2.
The invention also provides a method for preparing FGF-2, which is characterized by comprising the following steps:
a. culturing the cells: culturing a mammalian cell;
b. transfection: transfecting the mammalian cells obtained in step a with the construct as described above;
c. and (3) purification: FGF-2 was purified by affinity chromatography.
In a preferred embodiment, the affinity chromatography is performed by a heparin-binding domain.
In a preferred embodiment, in said step b, the mammalian cells obtained in step a are transfected with a construct as described above; the affinity chromatography is mediated by the intein DnaE.
In the method for producing FGF-2 of the present invention, although there is no particular limitation on mammalian cells, for example, HEK293T, HeLa, C2C12, etc. can be used. In a preferred embodiment, however, the mammalian cell is HEK 293T.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Examples
Materials and methods
Chemicals, plasmids and antibodies, all chemicals were purchased from Sigma-Aldrich (st. louis, MO), unless otherwise specified.
Construction of plasmid vector pNC1
As shown in B1 in fig. 1:
a. PCR (using GeneArt Strings Gene Synthesis service (Thermo-Fisher Scientific, Waltham, Mass.)) was used to synthesize an enhancer sequence, which is a DNA sequence containing the DNA sequence of the NF-. kappa.B binding site and the DNA sequence of the CREB binding site;
b. plasmid vector pcDNA was digested with NheI and HindIII 3.1 (+);
c. digesting the DNA sequence synthesized in the step a by using NheI and HindIII;
d. ligating the digested plasmid vector pcDNA3.1(+) obtained in step b with the digested DNA sequence obtained in step c using a ligase.
The sequence was confirmed by Sanger sequencing.
The specific process is as follows:
material
pcDNA3.1(+) was purchased from Thermo Scientific, USA, and its vector map is shown in FIG. 1A. Restriction enzymes NheI and HindIII, and T4DNA Ligase were purchased from NEB. Plasmid extraction kit and DNA fragment recovery kit were purchased from Thermo Scientific.
Enhancer PCR amplification
The enhancer template is synthesized by GeneArt string service (thermos scientific), and the DNA sequence of the enhancer is shown in SEQ ID NO. 5: 5'
GGAAATCCCCGGAAATCCCCGTAAAATTTGCGTCAACACTGCTC AAC are provided. The forward and reverse primers used are shown in Table 1. The following reactants were added to the EP tube in order: mu.l of template, 1 Xbuffer, 1. mu.M forward primer, 1. mu.M reverse primer, 0.5. mu.l polymerase, 4. mu.l dNTP, and ddH2O to 50. mu.l of reaction system.
Reaction conditions are as follows: 95 deg.C for 5 min; 95 ℃ for 15 s; 55 ℃ for 10 s; 72 ℃ for 10 s; 35 cycles; extension was carried out at 72 ℃ for 10min and the reaction was stopped at 4 ℃.
And (3) carrying out electrophoresis on the PCR amplification product in 3% agarose gel to detect the result, and recovering the insert band by using a DNA gel recovery and purification kit. A59 bp fragment was obtained, consistent with the expected size.
The PCR-recovered product was ligated with the plasmid vector pcDNA3.1(+)
The PCR recovered fragment and the plasmid vector pcDNA3.1(+) are cut by NheI and HindIII enzyme and then are connected by T4DNA ligase, the connection product is transformed into a chemically competent cell DH5a strain and is coated on a plate of an ampicillin resistant solid culture medium, a plurality of monoclonal colonies are picked and inoculated into an ampicillin resistant liquid culture medium, and the ampicillin resistant liquid culture medium is subjected to shaking culture at the constant temperature of 37 ℃ and 250rpm overnight. And extracting the plasmid by using a plasmid extraction kit to obtain a recombinant plasmid vector pNC 1.
Identification of recombinant plasmid vector pNC1
The NheI and HindIII enzyme digestion is used for identification, and the enzyme digestion identification system and the reaction conditions are as follows:
The total volume was 20. mu.L. 37 ℃ for 15 min.
And (5) enzyme digestion identification is carried out, and the obtained product is consistent with the expected analysis size.
And (3) selecting positive clones which are subjected to enzyme digestion verification to carry out sequencing analysis, and verifying the correctness of the recombinant plasmid vector by FinchTV analysis and BLAST software comparison. The analysis result shows that the nucleotide sequence of the enhancer is completely correct, and the recombinant plasmid vector pNC1 is successfully obtained.
FGF2-pcDNA3.1(+) construct, FGF2-pNC1 construct and his-DnaE-FGF2-pNC1 construct
The DNA sequence (amino acids 143-288, PRO-0000008933) of the fgf2 gene (i.e., the mature functional fragment of the fgf2 gene) without the propeptide sequence was designed for codon optimization in humans.
The designed FGF2 gene was synthesized using GeneArt Strings Gene Synthesis service (Thermo-Fisher Scientific, Waltham, Mass.), and the synthesized FGF2 gene was cloned into pcDNA3.1(+) and pNC1 with EcoRI and NotI sites to form the FGF2-pcDNA3.1(+) construct and the FGF2-pNC1 construct, as shown in FIGS. 1A,1B 2. All sequences were confirmed by Sanger sequencing.
To optimize purification, the present invention uses the 6x his tag and uses the DNA polymerase iii (dnae) intein of Nostoc punctiforme (Nostoc punctiforme) PCC73102(Npu) fused with the FGF2 gene to facilitate purification of human fibroblast growth factor 2(FGF 2).
Designed fgf2 and 6x his-Npu DnaE intein genes were synthesized using GeneArt strands gene synthesis service (Thermo-Fisher Scientific, Waltham, MA). The 6x his-Npu DnaE intein was fused to fgf2 by overlap PCR.
To further increase expression of fgf2, an enhancer sequence containing NF-. kappa.B binding sites and CREB binding sites was synthesized using the GeneArt Strings Gene Synthesis service and cloned into pcDNA3.1(+) with NheI and HindIII sites (Thermo-Fisher Scientific, Waltham, Mass)) to form the expression plasmid vector pNC 1. Synthetic 6xhis-DnaE-FGF2) was cloned into pNC1 with EcoRI and NotI sites to form the his-DnaE-FGF2-pNC1 construct, as shown in fig. 1C. All sequences were confirmed by Sanger sequencing. Antibodies used for western blotting: mouse FGF-2 (clone C-2, Santa Cruz Biotechnology, Dallas, TX), mouse anti-beta-actin (Sigma, St. Louis, MO).
The specific process of constructing the FGF2-pcDNA3.1(+) construct is as follows:
fgf2 Gene PCR amplification
fgf2 the template was synthesized by GeneArt Stringservice (thermos scientific), and its DNA sequence is shown in SEQ ID NO.1
CCGGCTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCCA CCAGGACACTTCAAAGATCCGAAGAGGCTTTACTGCAAGAATG GTGGATTTTTCCTCCGCATCCATCCAGACGGTCGGGTGGACGGC GTACGGGAGAAATCCGATCCGCATATAAAGCTGCAGCTGCAAG CTGAAGAACGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTAA TAGGTACCTTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCTA AGTGCGTGACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTCA AACAATTATAACACCTATAGGTCAAGAAAGTATACGAGCTGGT ACGTTGCCCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCAA AACAGGCCCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGTG CCAAGTCTTAATAATAA are provided. The forward and reverse primers used are shown in Table 1. The following reactants were added to the EP tube in order: mu.l of template, 1 Xbuffer, 1. mu.M forward primer, 1. mu.M reverse primer, 0.5. mu.l polymerase, 4. mu.l dNTP, and ddH2O to 50. mu.l of reaction system.
Reaction conditions are as follows: 95 deg.C for 5 min; 95 ℃ for 15 s; 55 ℃ for 10 s; 72 ℃ for 30 min; 35 cycles; extension was carried out at 72 ℃ for 10min and the reaction was stopped at 4 ℃.
And (3) carrying out electrophoresis on the PCR amplification product in 1% agarose gel to detect the result, and recovering the insert band by using a DNA gel recovery and purification kit. A460 bp fragment was obtained, consistent with the expected size.
The PCR-recovered product was ligated with the plasmid vector pcDNA3.1(+)
The PCR recovered fragment and the plasmid vector pcDNA3.1(+) are cut by EcoRI and NotI and then are connected by T4DNA ligase, the connection product is transformed into a chemically competent cell DH5a strain and is coated on a plate of an ampicillin resistant solid culture medium, a plurality of monoclonal colonies are picked and inoculated into an ampicillin resistant liquid culture medium, and the mixture is subjected to shaking culture at 37 ℃ and 250rpm overnight by a constant temperature shaking table. Extracting the plasmid by using a plasmid extraction kit to obtain the FGF2-pcDNA3.1(+) construct.
Identification of FGF2-pcDNA3.1(+) construct
The restriction enzyme digestion is carried out by EcoRI and NotI, and the restriction enzyme digestion identification system and the reaction conditions are as follows:
FGF2-pcDNA3.1(+) construct 5. mu.L, 10 Xbuffer 2. mu.L, EcoRI 0.5. mu.L, NotI 0.5. mu.L, ddH2O 11. mu.L in total volume 20. mu.L. 37 ℃ for 15 min.
And (5) enzyme digestion identification is carried out, and the obtained product is consistent with the expected analysis size.
And selecting a positive clone with correct enzyme digestion verification for sequencing analysis, and comparing the result by FinchTVV analysis and BLAST software to verify the correctness of the FGF2-pcDNA3.1(+) construct. The analysis result shows that the FGF2 nucleotide sequence is completely correct, and the FGF2-pcDNA3.1(+) construct is successfully obtained.
The construction of the FGF2-pNC1 construct is specifically as follows:
fgf2 Gene PCR amplification
fgf2, the DNA sequence of which is shown in SEQ ID NO. 1:
CCGGCTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCCACCAG GACACTTCAAAGATCCGAAGAGGCTTTACTGCAAGAATGGTGG ATTTTTCCTCCGCATCCATCCAGACGGTCGGGTGGACGGCGTAC GGGAGAAATCCGATCCGCATATAAAGCTGCAGCTGCAAGCTGA AGAACGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTAATAGG TACCTTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCTAAGTG CGTGACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTCAAACA ATTATAACACCTATAGGTCAAGAAAGTATACGAGCTGGTACGT TGCCCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCAAAACA GGCCCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGTGCCAA GTCTTAATAATAA are provided. The forward and reverse primers used are shown in Table 1. The following reactants were added to the EP tube in order: mu.l of template, 1 Xbuffer, 1. mu.M forward primer, 1. mu.M reverse primer, 0.5. mu.l polymerase, 4. mu.l dNTP, and ddH2O to 50. mu.l of reaction system.
Reaction conditions are as follows: 95 deg.C for 5 min; 95 ℃ for 15 s; 55 ℃ for 10 s; 72 ℃ for 30 min; 35 cycles; extension was carried out at 72 ℃ for 10min and the reaction was stopped at 4 ℃. And (3) carrying out electrophoresis on the PCR amplification product in 1% agarose gel to detect the result, and recovering the insert band by using a DNA gel recovery and purification kit. A460 bp fragment was obtained, consistent with the expected size.
The PCR-recovered product was ligated with the plasmid vector pNC1
The PCR recovered fragment and the plasmid vector pNC1 were digested with EcoRI and NotI, ligated with T4DNA ligase, the ligation product was transformed into chemically competent cell strain DH5a, spread on a plate of ampicillin resistant solid medium, several monoclonal colonies were picked up and inoculated into ampicillin resistant liquid medium, and shake-cultured overnight at 37 ℃ and 250rpm on a constant temperature shaker. Plasmids were extracted using a plasmid extraction kit to obtain pNC1 constructs.
Identification of FGF2-pNC1 construct
The restriction enzyme digestion is carried out by EcoRI and NotI, and the restriction enzyme digestion identification system and the reaction conditions are as follows:
FGF2-pNC1 construct 5. mu.L, 10 Xbuffer 2. mu.L, EcoRI 0.5. mu.L, NotI 0.5. mu.L, ddH2O11. mu.L in a total volume of 20. mu.L. 37 ℃ for 15 min. And (5) enzyme digestion identification is carried out, and the obtained product is consistent with the expected analysis size.
And selecting positive clones with correct enzyme digestion verification for sequencing analysis, and comparing the results through FinchTV analysis and BLAST software to verify the correctness of the FGF2-pNC1 construct. The analysis result shows that the FGF2 nucleotide sequence is completely correct, and the FGF2-pNC1 construct is successfully obtained.
The specific process for constructing the his-DnaE-FGF2-pNC1 construct is as follows:
fusion PCR amplification of his-DnaE-FGF2
The template of his-DnaE-FGF2 was synthesized by GeneArt string service (thermos scientific), and its DNA sequence is shown in SEQ ID NO. 2:
CATCATCACCATCACCACGCCGAGTACTACGAGACCGAGATCC TGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATCGTGGA GAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACAACGGC AACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAGGGGCG AGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGCCTGAT CAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACGGCCAG ATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGACCTGA TGAGGGTGGACAACCTGCCCAACGCCGAGTACTACGAGACCGA GATCCTGACCGTGGAGTACGGCCTGCTGCCCATCGGCAAGATC GTGGAGAAGAGGATCGAGTGCACCGTGTACAGCGTGGACAACA ACGGCAACATCTACACCCAGCCCGTGGCCCAGTGGCACGACAG GGGCGAGCAGGAGGTGTTCGAGTACTGCCTGGAGGACGGCAGC CTGATCAGGGCCACCAAGGACCACAAGTTCATGACCGTGGACG GCCAGATGCTGCCCATCGACGAGATCTTCGAGAGGGAGCTGGA CCTGATGAGGGTGGACAACCTGCCCAACCCGGCTCTCCCAGAG GATGGCGGCTCAGGAGCCTTTCCACCAGGACACTTCAAAGATC CGAAGAGGCTTTACTGCAAGAATGGTGGATTTTTCCTCCGCATC CATCCAGACGGTCGGGTGGACGGCGTACGGGAGAAATCCGATC CGCATATAAAGCTGCAGCTGCAAGCTGAAGAACGAGGGGTGGT TAGCATAAAGGGCGTGTGTGCTAATAGGTACCTTGCCATGAAA GAAGACGGACGGCTCCTCGCTTCTAAGTGCGTGACCGACGAGT GCTTCTTCTTTGAGCGGCTAGAGTCAAACAATTATAACACCTAT AGGTCAAGAAAGTATACGAGCTGGTACGTTGCCCTTAAGCGGA CCGGCCAGTACAAGCTTGGTAGCAAAACAGGCCCTGGCCAGAA GGCTATCCTCTTCCTCCCTATGAGTGCCAAGTCTTAATAATAA are provided. The forward and reverse primers used with the His-DnaE forward primer and FGF2 reverse primer are shown in Table 1. The following reactants were added to the EP tube in order: mu.l of template, 1 Xbuffer, 1. mu.M forward primer, 1. mu.M reverse primer, 0.5. mu.l polymerase, 4. mu.l dNTP, and ddH2O to 50. mu.l of reaction system.
Reaction conditions are as follows: 95 deg.C for 5 min; 95 ℃ for 15 s; 55 ℃ for 10 s; 72 ℃ for 30 min; 35 cycles; extension was carried out at 72 ℃ for 10min and the reaction was stopped at 4 ℃. And (3) carrying out electrophoresis on the PCR amplification product in 1% agarose gel to detect the result, and recovering a GFP strip by using a DNA gel recovery and purification kit. A1097 bp fragment was obtained, consistent with the expected size.
The PCR-recovered product was ligated with the plasmid vector his-DnaE-FGF2
The PCR recovered fragment and the plasmid vector his-DnaE-FGF2 are cut by EcoRI and NotI, then are connected by T4DNA ligase, the connection product is transformed into a chemically competent cell DH5a strain, the strain is coated on a plate of an ampicillin resistant solid culture medium, a plurality of monoclonal colonies are picked up and inoculated into an ampicillin resistant liquid culture medium, and the ampicillin resistant liquid culture medium is subjected to shaking culture at the constant temperature of 37 ℃ and 250rpm overnight. And extracting the plasmid by using a plasmid extraction kit to obtain the his-DnaE-FGF2 construction body.
Identification of his-DnaE-FGF2 construct
The restriction enzyme digestion is carried out by EcoRI and NotI, and the restriction enzyme digestion identification system and the reaction conditions are as follows:
the his-DnaE-FGF2 construct 5. mu.L, 10 Xbuffer 2. mu.L, EcoRI 0.5. mu.L, NotI 0.5. mu.L, ddH2O 11. mu.L in total volume 20. mu.L. 37 ℃ for 15 min.
And (5) enzyme digestion identification is carried out, and the obtained product is consistent with the expected analysis size.
And selecting positive clones with correct enzyme digestion verification for sequencing analysis, and comparing the results with FinchTV analysis and BLAST software to verify the correctness of the his-DnaE-FGF2 construct. The analysis result shows that the his-DnaE-FGF2 nucleotide sequence is completely correct, and the his-DnaE-FGF2 construct is successfully obtained.
TABLE 1
The DNA containing NheI and HindIII restriction site enhancers synthesized by PCR was SEQ ID NO.11 (i.e., SEQ ID NO.5 containing NheI and HindIII restriction sites):
GCTAGCGGAAATCCCCGGAAATCCCCGTAAAATTTGCGTCAAC ACTGCTCAACAAGCTT。
the DNA sequence of FGF2 synthesized by PCR and containing restriction sites for EcoRI and NotI is SEQ ID NO.12 (i.e., SEQ ID NO.1 containing restriction sites for EcoRI and NotI):
GAATTCCCGGCTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCC ACCAGGACACTTCAAAGATCCGAAGAGGCTTTACTGCAAGAAT GGTGGATTTTTCCTCCGCATCCATCCAGACGGTCGGGTGGACGG CGTACGGGAGAAATCCGATCCGCATATAAAGCTGCAGCTGCAA GCTGAAGAACGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTA ATAGGTACCTTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCT AAGTGCGTGACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTC AAACAATTATAACACCTATAGGTCAAGAAAGTATACGAGCTGG TACGTTGCCCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCA AAACAGGCCCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGT GCCAAGTCTTAATAATAAGCGGCCGC。
the DNA sequence of the PCR-synthesized his-DnaE-FGF2 with restriction sites for EcoRI and NotI is SEQ ID NO.13 (i.e., SEQ ID NO.2 with restriction sites for EcoRI and NotI):
GAATTCACCATGCATCATCACCATCACCACGCCGAGTACTACGA GACCGAGATCCTGACCGTGGAGTACGGCCTGCTGCCCATCGGC AAGATCGTGGAGAAGAGGATCGAGTGCACCGTGTACAGCGTGG ACAACAACGGCAACATCTACACCCAGCCCGTGGCCCAGTGGCA CGACAGGGGCGAGCAGGAGGTGTTCGAGTACTGCCTGGAGGAC GGCAGCCTGATCAGGGCCACCAAGGACCACAAGTTCATGACCG TGGACGGCCAGATGCTGCCCATCGACGAGATCTTCGAGAGGGA GCTGGACCTGATGAGGGTGGACAACCTGCCCAACGCCGAGTAC TACGAGACCGAGATCCTGACCGTGGAGTACGGCCTGCTGCCCA TCGGCAAGATCGTGGAGAAGAGGATCGAGTGCACCGTGTACAG CGTGGACAACAACGGCAACATCTACACCCAGCCCGTGGCCCAG TGGCACGACAGGGGCGAGCAGGAGGTGTTCGAGTACTGCCTGG AGGACGGCAGCCTGATCAGGGCCACCAAGGACCACAAGTTCAT GACCGTGGACGGCCAGATGCTGCCCATCGACGAGATCTTCGAG AGGGAGCTGGACCTGATGAGGGTGGACAACCTGCCCAACCCGG CTCTCCCAGAGGATGGCGGCTCAGGAGCCTTTCCACCAGGACA CTTCAAAGATCCGAAGAGGCTTTACTGCAAGAATGGTGGATTTT TCCTCCGCATCCATCCAGACGGTCGGGTGGACGGCGTACGGGA GAAATCCGATCCGCATATAAAGCTGCAGCTGCAAGCTGAAGAA CGAGGGGTGGTTAGCATAAAGGGCGTGTGTGCTAATAGGTACC TTGCCATGAAAGAAGACGGACGGCTCCTCGCTTCTAAGTGCGT GACCGACGAGTGCTTCTTCTTTGAGCGGCTAGAGTCAAACAATT ATAACACCTATAGGTCAAGAAAGTATACGAGCTGGTACGTTGC CCTTAAGCGGACCGGCCAGTACAAGCTTGGTAGCAAAACAGGC CCTGGCCAGAAGGCTATCCTCTTCCTCCCTATGAGTGCCAAGTC TTAATAATAAGCGGCCGC。
cell culture and transfection
HEK293T and C2C12 cells were maintained in DMEM containing 10 vol% FBS and 1 vol% penicillin streptomycin solution (Thermo-Fisher Scientific, Waltham, MA) at ambient temperature of 37 ℃ with 5% CO 2. PC12 cells were maintained in DMEM containing 10 vol% HS, 5 vol% FBS and 1 vol% penicillin streptomycin solution at ambient temperature of 37 ℃ containing 5% CO 2. pcDNA3.1-FGF2, pNC1-FGF2 and pNC1-6xhis-DnaE-FGF2 constructs were transfected into HEK293T using Lipofectamine 2000(Thermo-Fisher Scientific, Waltham, Mass.) according to the manufacturer's instructions.
Purification of FGF2
The medium was collected and spun at 2,000g for 10 minutes to remove cell debris and filtered through a 0.45 μm filter. The filtrate was then passed through a pre-packed heparin-agarose column (BioRad Laboratories, Hercules, Calif.) equilibrated with 50mM Tris-HCl (pH 7.5). The column was washed thoroughly with 50mM Tris-HCl (pH7.5), 0.2M NaCl. FGF2 was eluted with a NaCl gradient from 0.3M to 3M (4-5 bed volumes for gradient). After elution, the protein was passed through a pre-packed Sephadex G25 column equilibrated with 50mM Tris-HCl (pH7.5) and eluted with the same buffer.
For intracellular expressed FGF2, cells were washed three times with ice-cold TBS and then sonicated in lysis buffer (TBS supplied with a Cocktail of clomplete tm Protease inhibitors (clomplete tm Protease Inhibitor Cocktail)). FGF2 was then purified in culture medium.
To obtain intein cleaved FGF2, histidine-tagged DnaE-FGF2 was purified by prepackaged Ni-NTA column. After washing, the column was incubated in 50mM Tris-HCl (pH6.2), 10mM EDTA, 200mM NaCl at 22 ℃ for different durations of 0, 1, 2, 4, 6, 10 hours, respectively, to induce C-terminal cleavage of the DnaE intein.
Protein analysis
Proteins were separated on a 15% by volume Tris-glycine SDS-PAGE. The gel was stained with silver to obtain purified protein. On the gel, the band corresponding to FGF2 was excised, washed and incubated with 1. mu.g trypsin in 50mM NH 4HCO 3 overnight at 4 ℃. The hydrolyzed samples were analyzed by LTQ Velos Linear Ion Trap Mass Spectrometers (Thermo Fisher scientific, San Jose) coupled to an Accela HPLE system. Complete MS scans (300-. For cell lysates, samples were spotted or transferred onto 0.2 μmNC membranes (BioRad Laboratories, Hercules, CA) and then blotted with antibodies (mouse FGF-2 (clone C-2, Santa Cruz Biotechnology, Dallas, TX), mouse anti- β -actin (Sigma, st. louis, MO)).
Biological assay for FGF2
To monitor the effect of FGF2 on cell proliferation, MTT assays were performed as previously described. Briefly, C2C12 cells were seeded in 96-well plates and DMEM +0.5 vol% FBS and 1ng/mL of commercially available FGF2, purified FGF2 and endopeptidase cleaved FGF2 were provided. The activity of the cells was determined by adding MTT to a final concentration of 1mg/mL and incubated at 37 ℃ for 6 hours. The medium was then replaced with DMSO and the absorbance measured at 540nm in a microplate reader.
To test the neurotrophic effect of FGF2, PC12 cells were cultured for 3 days with medium supplied with 2ng/mL of FGF 2. The morphology of the cells was observed, and images were taken by phase contrast optical microscopy.
Results
Construction of a plasmid expressing human identical exogenous FGF2
The full length FGF2 protein consists of 288 amino acids, with amino acids 1-142 cleaved and removed to yield functional FGF 2. Thus, the protein sequence of amino acid 143-288 was codon optimized for Homo sapiens (Homo sapiens). To explore the feasibility of maximizing protein expression, the NF-. kappa.B binding site and CREB binding site enhancer sequences were cloned into pcDNA3.1 vector containing the native CMV immediate early promoter/enhancer sequence. The synthesized fgf2 gene was then cloned into pcDNA3.1 and pNC1 vectors (FIG. 1) for comparison of expression of the two clones in mammalian cells. Experiments have shown that the pNC1 vector greatly increased the expression level of FGF2 in mammalian cells, as shown in fig. 2. The neomycin resistance gene also provides a selectable marker by G418 sulfate. Stably transfected cells can thus be selected for purification of human identical exogenous FGF 2.
Expression of soluble FGF2 in HEK293T cells
HEK293T cells were selected for purification because of their ease of transfection. The SV40 large T antigen also provides the ability of cells to replicate transfection plasmids, which contain the SV40 origin of replication. Furthermore, the CMV promoter is one of the strongest promoters and is constitutively active in HEK293T cells. While HEK293T cells are adherent cells, their suitability for suspension culture is versatile and therefore advantageous for expanding the production of FGF 2. The pcDNA3.1-FGF2pNC1-FGF2 and pNC1-6xhis-DnaE-FGF2 constructs were transiently transfected into HEK293T cells and expression was monitored. Experiments show that: the pNC1 vector greatly increased the expression level of FGF2 (fig. 2A, 2B). Expression of FGF2 peaked 48 hours after transfection and remained stable at longer time points.
One of the drawbacks of protein preparation and purification using bacterial systems is the formation of insoluble aggregates. To test the solubility of FGF2 expressed in HEK293T cells, pellet fractions were harvested from cell lysates. The insoluble fraction was sonicated in Laemmili sample buffer and then electrophoresed in SDS-PAGE. Western blot of lysates showed that most of FGF2 was soluble (fig. 2C). Compared with the FGF2 standard, FGF2 expressed in pcDNA3.1-FGF2 was about 20 μ g/mL, and FGF2 expressed in pNC1-FGF2 was about 50 μ g/mL.
Purification and protein sequencing of FGF2
To maximize the yield of purified FGF2, HEK293T cells were transfected with pNC1-FGF 2. 48 hours after transfection, cells were harvested and lysed to purify FGF2 expressed intracellularly. FGF2 was purified by heparin-agarose affinity chromatography followed by size exclusion chromatography. Eluted FGF2 was electrophoresed on 15% SDS-PAGE (FIG. 3A). Samples were lyophilized and reconstituted in 0.1x PBS. To check the purity of FGF2, silver staining was performed after electrophoresis and showed very high purity, only 1 weak band was found above purified FGF2 (fig. 3B). The yield was also satisfactory. To identify purified FGF2, bands on SDS-PAGE were excised, solubilized, and analyzed by LC-MS after trypsinization. Sequencing results showed that the primary structure of purified FGF2 was identical to mature exogenous human FGF2 (table 2). Thus, we expect purified FGF2 to exhibit the same properties, activities, and functions as the human natural counterpart.
FGF2 expressed by HEK293T has biological activity
FGF2 has been shown to stimulate cell growth in a number of cell types. After confirming the primary structure of purified FGF2, we treated cultured C2C12 with 1ng/mL of purified and commercially available FGF2, PBS serving as a control. The viability of the cultured cells was then measured by MTT assay (fig. 4A). Both FGF2 samples were able to stimulate proliferation of C2C12 cells. Purified FGF2 showed similar or even higher biological activity than commercial FGF2, but the difference was not significant. FGF2 also exhibits neurotrophic activity in neuronal cell lines. Thus, the neurotrophic activity of purified FGF2 was tested in PC12 cells. After 3 days of FGF2 treatment, prolonged neurite outgrowth was observed, which was absent in the PBS control group (fig. 4B). The data demonstrate that purified FGF2 is biologically active and has activity similar to that of commercially available FGF 2.
Intein-mediated purification in HEK293T cells
A recombinant protein cascade containing 6 × histidine-tagged DnaE-FGF2 was cloned into pNC1 vector (FIG. 1C) and then transfected into HEK293T cells. The medium was collected and spun at 2,000g for 10 minutes to remove cell debris and filtered through a 0.45 μm filter. The protein was purified by Ni-NTA affinity chromatography. FGF2 excision was performed on Ni-NTA columns with lysis buffer (50mM Tris-HCl pH6.2, 10mM EDTA, 200mM NaCl) at different time points at 22 ℃. The beads and supernatant were boiled in 2x Laemmili sample buffer to elute bead-bound proteins, followed by SDS-PAGE (fig. 5). The experimental results show that complete cleavage of inteins requires at least 5 hours of incubation. The identity of the cleaved protein was determined by LC-MS and the primary sequence of the cleaved FGF2 was found to be identical to mature human FGF2 (table 3). The biological activity of cleaved FGF2 on C2C12 cells was also tested, and the performance of endoproteolytic cleaved FGF2 was also identical to purified FGF2 (fig. 6A, 6B).
TABLE 2
Liquid chromatography-tandem mass spectrometry analysis of purified FGF2
aAfter trypsin partial digestion of purified FGF2, the N-terminal and C-terminal sequences were identified by Mascot search engine
bTheoretical mass to charge ratio of peptide
cExperimental Mass to Charge ratios of peptides
TABLE 3
Analysis of intein-cleaved FGF2 by liquid chromatography-tandem mass spectrometry
aAfter trypsin partial digestion of purified FGF2, the N-terminal and C-terminal sequences were identified by Mascot search engine
bTheoretical mass to charge ratio of peptide
cExperimental Mass to Charge ratios of peptides
FGF2 is a highly valuable protein with a wide range of potency including angiogenesis, neurogenesis and wound healing. One of the reasons impeding the research of the medical use of FGF2 is the high cost of purification and bioactive FGF 2. Using HEK293T cells, we successfully expressed and purified human FGF2 (fig. 3). The silver stained gel proved to be very satisfactory in purity. Purified FGF2 showed the same mitogenic or neurotrophic activity as commercially available FGF2 in C2C12 and PC12 cell cultures. This simple protocol allows for laboratory scale production of human exogenous FGF2 in mammalian systems and can be easily scaled up for large scale production.
One of the most widely used host systems for FGF2 purification is bacteria. However, simple prokaryotes lack the necessary post-translational modifications, including splicing, glycosylation and disulfide bonding, activity and solubility of the protein for purification. The natural folding of the purified protein is critical to its function and solubility. Protein aggregates or inclusion bodies are often found when eukaryotic proteins are expressed in bacterial systems. Methods involving inducing proteins or denaturing and renaturing protein aggregates at lower temperatures do not always produce good yields. Another problem with bacterial systems is endotoxins. Lipopolysaccharides or endotoxins are usually present in E.coli. The presence of endotoxin triggers an immune response in humans and may lead to septic shock. Although there are commercially available kits and protocols for removing endotoxin, contamination with endotoxin is generally unavoidable. However, the above problems can be easily overcome using mammalian cells.
Using mammalian cells to express proteins, we were able to purify functional, correctly folded and modified proteins (table 2, fig. 3, fig. 4). Therefore, we succeeded in purifying unlabeled human mature exogenous FGF2 in mammalian cells for the first time.
In the present invention, we have demonstrated that DnaE is a fast-cutting intein in HEK293T cells. By using this intein we have demonstrated that the primary structure (table 3) and biological activity (figure 6) of the cleaved FGF2 is identical to its natural counterpart. The medical use of purified FGF2 will be extensive. In addition, the plasmid vector pNC1 can be used to express a variety of valuable proteins.
Sequence listing
<110> root of Bell Tree
<120> production of human embryonic cytokine-1 by using optimized FGF2 gene functional region sequence
<130> 190064882
<160> 13
<170> PatentIn version 3.5
<210> 1
<211> 447
<212> DNA
<213> Artificial Synthesis
<400> 1
ccggctctcc cagaggatgg cggctcagga gcctttccac caggacactt caaagatccg 60
aagaggcttt actgcaagaa tggtggattt ttcctccgca tccatccaga cggtcgggtg 120
gacggcgtac gggagaaatc cgatccgcat ataaagctgc agctgcaagc tgaagaacga 180
ggggtggtta gcataaaggg cgtgtgtgct aataggtacc ttgccatgaa agaagacgga 240
cggctcctcg cttctaagtg cgtgaccgac gagtgcttct tctttgagcg gctagagtca 300
aacaattata acacctatag gtcaagaaag tatacgagct ggtacgttgc ccttaagcgg 360
accggccagt acaagcttgg tagcaaaaca ggccctggcc agaaggctat cctcttcctc 420
cctatgagtgccaagtcttaataataa 447
<210> 2
<211> 1077
<212> DNA
<213> Artificial Synthesis
<400> 2
catcatcacc atcaccacgc cgagtactac gagaccgaga tcctgaccgt ggagtacggc 60
ctgctgccca tcggcaagat cgtggagaag aggatcgagt gcaccgtgta cagcgtggac 120
aacaacggca acatctacac ccagcccgtg gcccagtggc acgacagggg cgagcaggag 180
gtgttcgagt actgcctgga ggacggcagc ctgatcaggg ccaccaagga ccacaagttc 240
atgaccgtgg acggccagat gctgcccatc gacgagatct tcgagaggga gctggacctg 300
atgagggtgg acaacctgcc caacgccgag tactacgaga ccgagatcct gaccgtggag 360
tacggcctgc tgcccatcgg caagatcgtg gagaagagga tcgagtgcac cgtgtacagc 420
gtggacaaca acggcaacat ctacacccag cccgtggccc agtggcacga caggggcgag 480
caggaggtgt tcgagtactg cctggaggac ggcagcctga tcagggccac caaggaccac 540
aagttcatga ccgtggacgg ccagatgctg cccatcgacg agatcttcga gagggagctg 600
gacctgatga gggtggacaa cctgcccaac ccggctctcc cagaggatgg cggctcagga 660
gcctttccac caggacactt caaagatccg aagaggcttt actgcaagaa tggtggattt 720
ttcctccgca tccatccaga cggtcgggtg gacggcgtac gggagaaatc cgatccgcat 780
ataaagctgc agctgcaagc tgaagaacga ggggtggtta gcataaaggg cgtgtgtgct 840
aataggtacc ttgccatgaa agaagacgga cggctcctcg cttctaagtg cgtgaccgac 900
gagtgcttct tctttgagcg gctagagtca aacaattata acacctatag gtcaagaaag 960
tatacgagct ggtacgttgc ccttaagcgg accggccagt acaagcttgg tagcaaaaca 1020
ggccctggcc agaaggctat cctcttcctc cctatgagtg ccaagtctta ataataa 1077
<210> 3
<211> 20
<212> DNA
<213> Artificial Synthesis
<400> 3
<210> 4
<211> 19
<212> DNA
<213> Artificial Synthesis
<400> 4
tgcgtcaaca ctgctcaac 19
<210> 5
<211> 47
<212> DNA
<213> Artificial Synthesis
<400> 5
ggaaatcccc ggaaatcccc gtaaaatttg cgtcaacact gctcaac 47
<210> 6
<211> 30
<212> DNA
<213> Artificial Synthesis
<400> 6
aaaagctagc ggaaatcccc ggaaatcccc 30
<210> 7
<211> 29
<212> DNA
<213> Artificial Synthesis
<400> 7
aaaaaagctt gttgagcagt gttgacgca 29
<210> 8
<211> 32
<212> DNA
<213> Artificial Synthesis
<400> 8
aaagaattcc caccatgcat catcaccacc at 32
<210> 9
<211> 31
<212> DNA
<213> Artificial Synthesis
<400> 9
aaagcggccg cttattatta agacttggca c 31
<210> 10
<211> 31
<212> DNA
<213> Artificial Synthesis
<400> 10
aaaagaattc gccaccatgc cggctctccc a 31
<210> 11
<211> 59
<212> DNA
<213> Artificial Synthesis
<400> 11
gctagcggaa atccccggaa atccccgtaa aatttgcgtc aacactgctc aacaagctt 59
<210> 12
<211> 461
<212> DNA
<213> Artificial Synthesis
<400> 12
gaattcccgg ctctcccaga ggatggcggc tcaggagcct ttccaccagg acacttcaaa 60
gatccgaaga ggctttactg caagaatggt ggatttttcc tccgcatcca tccagacggt 120
cgggtggacg gcgtacggga gaaatccgat ccgcatataa agctgcagct gcaagctgaa 180
gaacgagggg tggttagcat aaagggcgtg tgtgctaata ggtaccttgc catgaaagaa 240
gacggacggc tcctcgcttc taagtgcgtg accgacgagt gcttcttctt tgagcggcta 300
gagtcaaaca attataacac ctataggtca agaaagtata cgagctggta cgttgccctt 360
aagcggaccg gccagtacaa gcttggtagc aaaacaggcc ctggccagaa ggctatcctc 420
ttcctcccta tgagtgccaa gtcttaataa taagcggccg c 461
<210> 13
<211> 1097
<212> DNA
<213> Artificial Synthesis
<400> 13
gaattcacca tgcatcatca ccatcaccac gccgagtact acgagaccga gatcctgacc 60
gtggagtacg gcctgctgcc catcggcaag atcgtggaga agaggatcga gtgcaccgtg 120
tacagcgtgg acaacaacgg caacatctac acccagcccg tggcccagtg gcacgacagg 180
ggcgagcagg aggtgttcga gtactgcctg gaggacggca gcctgatcag ggccaccaag 240
gaccacaagt tcatgaccgt ggacggccag atgctgccca tcgacgagat cttcgagagg 300
gagctggacc tgatgagggt ggacaacctg cccaacgccg agtactacga gaccgagatc 360
ctgaccgtgg agtacggcct gctgcccatc ggcaagatcg tggagaagag gatcgagtgc 420
accgtgtaca gcgtggacaa caacggcaac atctacaccc agcccgtggc ccagtggcac 480
gacaggggcg agcaggaggt gttcgagtac tgcctggagg acggcagcct gatcagggcc 540
accaaggacc acaagttcat gaccgtggac ggccagatgc tgcccatcga cgagatcttc 600
gagagggagc tggacctgat gagggtggac aacctgccca acccggctct cccagaggat 660
ggcggctcag gagcctttcc accaggacac ttcaaagatc cgaagaggct ttactgcaag 720
aatggtggat ttttcctccg catccatcca gacggtcggg tggacggcgt acgggagaaa 780
tccgatccgc atataaagct gcagctgcaa gctgaagaac gaggggtggt tagcataaag 840
ggcgtgtgtg ctaataggta ccttgccatg aaagaagacg gacggctcct cgcttctaag 900
tgcgtgaccg acgagtgctt cttctttgag cggctagagt caaacaatta taacacctat 960
aggtcaagaa agtatacgag ctggtacgtt gcccttaagc ggaccggcca gtacaagctt 1020
ggtagcaaaa caggccctgg ccagaaggct atcctcttcc tccctatgag tgccaagtct 1080
taataataagcggccgc 1097
Claims (7)
1. A construct comprising the DNA sequence shown in SEQ ID No.2 between the EcoRI and NotI restriction sites of a plasmid vector pNC1, said pNC1 being formed by cloning the NF- κ B binding site and the CREB binding site behind the CMV promoter of pcDNA3.1 (+).
2. A method of making a construct, comprising the steps of:
a. synthesizing a DNA sequence shown in SEQ ID NO.2 containing EcoRI and NotI restriction enzyme cutting sites;
b. digesting the plasmid vector with EcoRI and NotI, and recovering the large fragment;
c. connecting the DNA sequence obtained in the step a with the large fragment obtained in the step b by adopting ligase;
d. c, transfecting the cell with the ligation product obtained in the step c, screening positive clones, and extracting plasmids;
wherein the plasmid vector is pcDNA3.1(+) or pNC1, the pNC1 is formed by cloning the NF-. kappa.B binding site and the CREB binding site behind the CMV promoter of pcDNA3.1 (+).
3. Use of the construct of claim 1 for expressing FGF-2.
4. A method of preparing FGF-2, the method comprising:
a. culturing the cells: culturing a mammalian cell;
b. transfection: transfecting the mammalian cell obtained in step a with the construct of claim 1;
c. and (3) purification: FGF-2 was purified by affinity chromatography.
5. The method for the preparation of FGF-2 according to claim 4, wherein the affinity chromatography is performed by a heparin-binding domain.
6. The method for preparing FGF-2 according to claim 4, wherein in step b, the mammalian cells obtained in step a are transfected with the construct of claim 1; the affinity chromatography is mediated by the intein DnaE.
7. The method for producing FGF-2 according to any of claims 4 to 6, wherein the mammalian cell is HEK 293T.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910543546.4A CN110777148B (en) | 2019-06-21 | 2019-06-21 | DNA sequences for expression of FGF-2 and methods for producing FGF-2 |
PCT/CN2020/079897 WO2020253287A1 (en) | 2019-06-21 | 2020-03-18 | Optimized fgf2 gene functional region sequence and use thereof in preparation of human fgf2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910543546.4A CN110777148B (en) | 2019-06-21 | 2019-06-21 | DNA sequences for expression of FGF-2 and methods for producing FGF-2 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110777148A CN110777148A (en) | 2020-02-11 |
CN110777148B true CN110777148B (en) | 2021-08-06 |
Family
ID=69383271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910543546.4A Active CN110777148B (en) | 2019-06-21 | 2019-06-21 | DNA sequences for expression of FGF-2 and methods for producing FGF-2 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110777148B (en) |
WO (1) | WO2020253287A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110777165B (en) * | 2019-06-21 | 2021-08-06 | 梦芊科技知识产权有限公司 | Enhancer sequence and plasmid vector, preparation method and application thereof, and transformant |
CN110777148B (en) * | 2019-06-21 | 2021-08-06 | 梦芊科技知识产权有限公司 | DNA sequences for expression of FGF-2 and methods for producing FGF-2 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL138529A0 (en) * | 2000-09-18 | 2003-09-17 | Yeda Res & Dev | High level expression of heterologous proteins |
CN103865932A (en) * | 2012-12-11 | 2014-06-18 | 武汉禾元生物科技有限公司 | Method for producing recombinant human basic fibroblast growth factor from paddy rice seeds |
WO2014161405A1 (en) * | 2013-04-03 | 2014-10-09 | Gene-Vinate Limited | Means and method for expression of authentic human epidermal growth factor and/or basic fibrolast growth factor in cytoplasm and/or culture medium of escherichia coli |
CN110777148B (en) * | 2019-06-21 | 2021-08-06 | 梦芊科技知识产权有限公司 | DNA sequences for expression of FGF-2 and methods for producing FGF-2 |
-
2019
- 2019-06-21 CN CN201910543546.4A patent/CN110777148B/en active Active
-
2020
- 2020-03-18 WO PCT/CN2020/079897 patent/WO2020253287A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110777148A (en) | 2020-02-11 |
WO2020253287A1 (en) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112375784B (en) | Method for preparing recombinant novel coronavirus Spike protein | |
JP4423542B2 (en) | Antibacterial polypeptide and use thereof | |
WO2006081430A9 (en) | Leader sequences for directing secretion of polypeptides and methods for production thereof | |
JP2003504081A (en) | Design of β-sheet protein with specific binding properties | |
CN110777148B (en) | DNA sequences for expression of FGF-2 and methods for producing FGF-2 | |
EP1220933B1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
NO177540B (en) | Method of Preparation of Heterologous Proteins in Bombyx Mori as well as Plasmid and Recombinant Bombyx Mori Nuclear Polyhedrosis Virus (BmNPV) | |
KR20220029571A (en) | AAV9 affinity agent | |
CN110777165B (en) | Enhancer sequence and plasmid vector, preparation method and application thereof, and transformant | |
TW201829774A (en) | Expression construct and method for producing proteins of interest | |
EP0587541A1 (en) | Process to purify the big-endothelin protein | |
CN109053875B (en) | Mutant IGF-1, recombinant plasmid, recombinant protein and application | |
CN113614103A (en) | Non-native NKG2D receptor that does not directly signal cells to which it is attached | |
JP2561122B2 (en) | Functional polypeptide | |
US20160333386A1 (en) | Use of peptidylglycine alpha-amidating monooxigenase (pam) for c-terminal amidation | |
CN110540601B (en) | Recombinant PLB-hEGF fusion protein and application thereof | |
CN114409800B (en) | Method for preparing recombinant cystatin C | |
KR20200041185A (en) | A Cell penetrating peptide and high throughput screening method thereof | |
CN116284246A (en) | Signal peptide, nucleic acid fragment, recombinant expression vector, host cell and application thereof | |
KR20230173093A (en) | affinity agent | |
CN115838437A (en) | Human NT-proBNP fusion protein and preparation method and application thereof | |
CN116615462A (en) | Expression techniques for antibody constructs | |
JPH06504669A (en) | 5-HT↓1↓x-receptor | |
JP2023094202A (en) | Method for cyclizing and purifying target protein from fusion protein including target protein, method for producing cyclized target protein from fusion protein including target protein, and fusion protein to be used for cyclizing and purifying target protein | |
KR20240000462A (en) | AAV2 affinity agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40016750 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |